<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The purpose of this article is to review the treatment of a patient with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who is commonly seen in practice-specifically, a middle-aged <z:mp ids='MP_0001261'>obese</z:mp> patient with micro- and macrovascular complications whose A1C rises after therapeutic intervention </plain></SENT>
<SENT sid="1" pm="."><plain>Discussion of <z:chebi fb="105" ids="17234">glucose</z:chebi> management, as well as <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, and <z:hpo ids='HP_0001513'>obesity</z:hpo> comorbidities, is included </plain></SENT>
<SENT sid="2" pm="."><plain>CONCLUSION: The key to successful treatment is individualization of targets and therapeutic choices </plain></SENT>
<SENT sid="3" pm="."><plain>GLP-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> have been shown to be effective in the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, including aiding with A1C reduction and <z:hpo ids='HP_0001824'>weight loss</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Using a combination of old and new treatments for the management of <z:mp ids='MP_0002055'>diabetes</z:mp> can help to improve outcomes </plain></SENT>
</text></document>